Rama Jasty-Rao | Faculty | Michigan ...

Dr. Rama Jasty

Claim this profile

C S Mott Children's Hospital

Studies Cancer
Studies Rhabdomyosarcoma
11 reported clinical trials
28 drugs studied

Area of expertise

1

Cancer

Rama Jasty has run 5 trials for Cancer. Some of their research focus areas include:

Stage I
Stage IV
Stage II
2

Rhabdomyosarcoma

Rama Jasty has run 3 trials for Rhabdomyosarcoma. Some of their research focus areas include:

FOXO1 fusion negative
FOXO1 fusion positive
Stage IV

Affiliated Hospitals

Image of trial facility.

C S Mott Children's Hospital

Image of trial facility.

University Of Michigan Comprehensive Cancer Center

Clinical Trials Rama Jasty is currently running

Image of trial facility.

Chemotherapy

for Cancer

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.

Recruiting

2 awards

Phase 3

26 criteria

Image of trial facility.

Chemotherapy

for Wilms Tumor

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).

Recruiting

1 award

Phase 2

12 criteria

More about Rama Jasty

Clinical Trial Related

8 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Rama Jasty has experience with

  • Cyclophosphamide
  • Dactinomycin
  • Carboplatin
  • Etoposide
  • Questionnaire Administration
  • Vincristine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Rama Jasty specialize in?

Is Rama Jasty currently recruiting for clinical trials?

Are there any treatments that Rama Jasty has studied deeply?

What is the best way to schedule an appointment with Rama Jasty?

What is the office address of Rama Jasty?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security